|
| Status |
Public on Jun 18, 2015 |
| Title |
Type II JAK2 Inhibitor NVP-CHZ868 is Active in Vitro and in Vivo Against JAK2-Dependent B-cell Acute Lymphoblastic Leukemias |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Gene expression profiling was performed to define transcriptional programs associated with response to type II JAK2 inhibitor NVP-CHZ868 alone or in combination with dexamethasone in vitro and in vivo.
|
| |
|
| Overall design |
MHH-CALL4 cells harboring a CRLF2 rearrangement and JAK2 I682F mutation were treated with vehicle, CHZ868, dexamethasone, or CHZ868 + dexamethasone combination for 12 hours in triplicate. RNA was then extracted for hybridization on Affymetrix microarrays.
CRLF2+ patient-derived xenografts (05-412, 05-440, and 05-537) were treated in vivo for 3 days with vehicle, CHZ868, dexamethasone, or CHZ868 + dexmathasone combination for 3 days and then sacrificed. Transcriptional profiling was performed on unselected splenocytes from these animals.
|
| |
|
| Contributor(s) |
Li LS, Chapuy B, Weinstock DM |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Sep 24, 2014 |
| Last update date |
Jun 18, 2015 |
| Contact name |
Loretta Li |
| E-mail(s) |
loretta_li@dfci.harvard.edu
|
| Organization name |
Dana-Farber Cancer Institute
|
| Department |
Medical Oncology
|
| Lab |
Weinstock Lab
|
| Street address |
450 Brookline Ave
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02215 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL19198 |
[HTA-2_0] Affymetrix Human Transcriptome Array 2.0 (CDF: hta20hsensgcdf_18.0.0.cdf, version 18) |
|
| Samples (24)
|
|
| Relations |
| BioProject |
PRJNA261873 |
Less...
More...